<DOC>
	<DOCNO>NCT00386490</DOCNO>
	<brief_summary>To demonstrate safety tolerance multiple , oral dos AT-1001</brief_summary>
	<brief_title>Safety AT-1001 Healthy Volunteers</brief_title>
	<detailed_description>Subjects complete screen thereafter admit clinic prior treatment . Three ( 3 ) cohort 8 ( 3:1 ratio drug placebo ) subject receive 250 Âµg , 1 mg , 4 mg AT-1001 matching placebo three time day 10 day . The subject evaluate safety screening , prior administration treatment , follow dose study drug . Serial blood sample collect pharmacokinetic determination baseline 2 hour post morning dose Days 1 , 2 , 5 , 6 10 . Blood pressure , pulse , temperature monitoring adverse event occur prior morning dose study day . An end study visit occur 7-10 day last dose . Subjects evaluate screening ( medical history , physical examination , vital sign , clinical laboratory testing , 12-lead electrocardiogram ) . A physical exam , vital sign , clinical laboratory test EKG conduct pre first dose . Vital sign , clinical laboratory test EKGs monitor post dose . Adverse event report monitor throughout study . At end study physical exam , clinical laboratory test EKG perform .</detailed_description>
	<criteria>Subject must generally good health free clinical disease may interfere study evaluation . BMI 18 30 . Subject use chronic medication within 30 day prior treatment ( exclude hormonal contraceptive ) Subject take medication within 14 day prior treatment ( exclude hormonal contraceptive , additional exception discretion Sponsor ) . Subject consume significant quantity alcohol ( &gt; 3 fl oz . ETOH ) within 2 day treatment visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2006</verification_date>
</DOC>